|
|||||
|
|
Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype |
|
| Authors: | Kian Kani Paymaneh D. Malihi Yuqiu Jiang Haiying Wang Yixin Wang Daniel L. Ruderman David B. Agus Parag Mallick Mitchell E. Gross |
| Affiliation: | 1. University of Southern California, Los Angeles, California;2. Veridex LLC, A Johnson & Johnson Company, Raritan, New Jersey;3. Stanford University, Stanford, California |
| Abstract: | |
| Keywords: | AGR2 neuroendocrine prostate cancer metastasis biomarker |